Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy

Stefania Gori, Alessandro Inno, Lorenzo Belluomini, Paolo Bocus, Zeno Bisoffi, Antonio Russo, Guido Arcaro

Research output: Contribution to journalReview articlepeer-review

Abstract

Gut microbiota is involved in gastrointestinal carcinogenesis. Also, it modulates the activity, efficacy and toxicity of several chemotherapy agents, such as gemcitabine, cyclophosphamide, irinotecan, cisplatin and 5-Fluorouracil, and target therapy, such as tyrosine kinase inhibitors. More recently, accumulating data suggest that the composition of gut microbiota may also affect efficacy and toxicity of cancer immunotherapy. Therefore, the manipulation of gut microbiota through antibiotics, probiotics, prebiotics or fecal transplantation has been investigating with the aim to improve efficacy and mitigate toxicity of anticancer drugs.

Original languageEnglish
Pages (from-to)139-147
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Volume143
DOIs
Publication statusPublished - Nov 2019

Keywords

  • 5-Fluorouracil
  • Cisplatin
  • Cyclophosphamide
  • Gemcitabine
  • Immune checkpoint inhibitors
  • Irinotecan
  • Microbiota
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy'. Together they form a unique fingerprint.

Cite this